Back to Search
Start Over
4'-Fluorouridine Is a Broad-Spectrum Orally Available First-Line Antiviral That May Improve Pandemic Preparedness.
- Source :
-
DNA and cell biology [DNA Cell Biol] 2022 Aug; Vol. 41 (8), pp. 699-704. Date of Electronic Publication: 2022 Jul 05. - Publication Year :
- 2022
-
Abstract
- The COVID-19 pandemic has highlighted the urgent need for the development of broad-spectrum antivirals to enhance preparedness against future spillover of zoonotic viruses with pandemic potential into the human population. Currently, the direct-acting orally available SARS-CoV-2 inhibitors molnupiravir and paxlovid are approved for human use under emergency use authorization. A promising next-generation therapeutic candidate is the orally available ribonucleoside analog 4'-fluorouridine (4'-FlU) that had potent antiviral efficacy against different viral targets, including SARS-CoV-2 in human organoids and animal models. Although a nucleoside analog inhibitor such as molnupiravir that targets the viral RNA-dependent RNA polymerase (RdRP) complex, 4'-FlU showed a distinct mechanism of activity, delayed chain termination, compared with molnupiravir's induction of viral error catastrophe. This review will focus on some currently approved and emerging medicines developed against SARS-CoV-2, examining their potential to form a pharmacological first-line defense against zoonotic viruses with pandemic potential.
Details
- Language :
- English
- ISSN :
- 1557-7430
- Volume :
- 41
- Issue :
- 8
- Database :
- MEDLINE
- Journal :
- DNA and cell biology
- Publication Type :
- Academic Journal
- Accession number :
- 35788144
- Full Text :
- https://doi.org/10.1089/dna.2022.0312